Evidence map›Paper›PMID 36561074›Full record

ArticleRSC medicinal chemistry2022

Red light active Pt(iv)-BODIPY prodrug as a mitochondria and endoplasmic reticulum targeted chemo-PDT agent.

Arpan Bera, Srishti Gautam, Somarupa Sahoo, Apurba Kumar Pal, Paturu Kondaiah, Akhil R Chakravarty

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Arpan BeraDepartment of Inorganic and Physical Chemistry, Indian Institute of Science Bangalore 560012 India arc@iisc.ac.in +91 80 22932533.
Srishti GautamDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science Bangalore 560012 India paturu@iisc.ac.in +91 80 22932688.
Somarupa SahooDepartment of Inorganic and Physical Chemistry, Indian Institute of Science Bangalore 560012 India arc@iisc.ac.in +91 80 22932533.
Apurba Kumar PalDepartment of Inorganic and Physical Chemistry, Indian Institute of Science Bangalore 560012 India arc@iisc.ac.in +91 80 22932533.
Paturu KondaiahDepartment of Molecular Reproduction, Development and Genetics, Indian Institute of Science Bangalore 560012 India paturu@iisc.ac.in +91 80 22932688.
Akhil R ChakravartyDepartment of Inorganic and Physical Chemistry, Indian Institute of Science Bangalore 560012 India arc@iisc.ac.in +91 80 22932533.ORCID https://orcid.org/0000-0002-6471-9167
Indian Institute of Science Bangalore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A cisplatin-based platinum(iv) prodrug, [Pt(NH

Identifiers

PMID36561074
PMCPMC9749958
OpenAlexW4292683015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.